A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment.

Trial Profile

A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Daptomycin (Primary) ; Cloxacillin; Nafcillin; Oxacillin; Vancomycin
  • Indications Bacteraemia; Skin infections; Staphylococcal infections
  • Focus Adverse reactions
  • Acronyms RENSE
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2012 Planned end date changed from 1 Jul 2015 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 May 2012 Planned end date changed from 1 Apr 2012 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top